DFFN Diffusion Pharmaceuticals Inc.

0.5
0  -1%
Previous Close 0.5
Open 0.51
Price To Book 0.9
Market Cap 16,792,705
Shares 33,418,319
Volume 2,363,209
Short Ratio
Av. Daily Volume 5,557,041
Stock charts supplied by TradingView

NewsSee all news

  1. Diffusion Pharmaceuticals Appoints Life Sciences Veteran Dr. Robert Cobuzzi, Jr. to its Board of Directors

    CHARLOTTESVILLE, Va., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion," the "Company," "we," "our" or "us"), a cutting-edge biotechnology company developing new treatments for

  2. Diffusion Pharmaceuticals Inc. Announces Closing of $3.5 Million Offering Priced At-the-Market

    CHARLOTTESVILLE, Va., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion," the "Company," "we," "our" or "us") today announced the closing of its previously announced registered

  3. CORRECTING and REPLACING – Diffusion Pharmaceuticals Inc. Announces $3.5 Million Registered Direct Offering Priced At-the-Market

    CHARLOTTESVILLE, Va., Dec. 12, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), please note that the pricing and figures in the first

  4. Diffusion Pharmaceuticals Presents Data Suggesting Optimized TSC Dosing Regimen Increases Survival in Newly Diagnosed Inoperable Glioblastoma Patients

    CHARLOTTESVILLE, Va., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving

  5. Diffusion Pharmaceuticals Presents Early Findings Showing Increased Survival in Lead-in Portion of Phase 3 Glioblastoma Study with TSC plus Standard of Care

    CHARLOTTESVILLE, Va., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial enrolling.
Trans sodium crocetinate (TSC)
Glioblastoma (GBM)
Phase 2 commencement of enrolment announced October 17, 2019.
Trans sodium crocetinate (TSC) - PHAST-TSC
Ischemic or hemorrhagic stroke

Latest News

  1. Diffusion Pharmaceuticals Appoints Life Sciences Veteran Dr. Robert Cobuzzi, Jr. to its Board of Directors

    CHARLOTTESVILLE, Va., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion," the "Company," "we," "our" or "us"), a cutting-edge biotechnology company developing new treatments for

  2. Diffusion Pharmaceuticals Inc. Announces Closing of $3.5 Million Offering Priced At-the-Market

    CHARLOTTESVILLE, Va., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion," the "Company," "we," "our" or "us") today announced the closing of its previously announced registered

  3. CORRECTING and REPLACING – Diffusion Pharmaceuticals Inc. Announces $3.5 Million Registered Direct Offering Priced At-the-Market

    CHARLOTTESVILLE, Va., Dec. 12, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), please note that the pricing and figures in the first

  4. Diffusion Pharmaceuticals Presents Data Suggesting Optimized TSC Dosing Regimen Increases Survival in Newly Diagnosed Inoperable Glioblastoma Patients

    CHARLOTTESVILLE, Va., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving

  5. Diffusion Pharmaceuticals Presents Early Findings Showing Increased Survival in Lead-in Portion of Phase 3 Glioblastoma Study with TSC plus Standard of Care

    CHARLOTTESVILLE, Va., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving

  6. Diffusion Pharmaceuticals Announces Closing of $4.0 Million Public Offering

    CHARLOTTESVILLE, Va., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion," the "Company," "we," "our" or "us") a clinical-stage biotechnology company developing new treatments

  7. Diffusion Pharmaceuticals Announces $4.0 Million Public Offering

    CHARLOTTESVILLE, Va., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or the "Company"), a clinical-stage biotechnology company developing new treatments for life-threatening

  8. Diffusion Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

    Commenced Patient Enrollment in Phase 2 On-Ambulance TSC Clinical Trial for the Treatment of Stroke Reported Favorable Safety Data in Glioblastoma Multiforme Phase 3 Run-in Study CHARLOTTESVILLE, Va., Nov. 11, 2019

  9. Diffusion Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    CHARLOTTESVILLE, Va., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving